Voluntary announcement abstracts of six studies published at 2026 ESMO
Filed with HKEX · Stock code 9887 · · 5 pages · English
Summary by 6ix AI
Notably, three studies have been selected for Proffered Paper presentations, including one as a Late-Breaking Abstract. The announcement aims to inform shareholders and potential investors about the latest developments in the company's research and clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Nanjing Leads Biolabs Co., Ltd. on 6ix
Earlier from Nanjing Leads Biolabs
- Voluntary announcement first patient enrolled in phase ib/II clinical trial of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) in combination therapy for metastatic colorectal cancer
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Fast Track Designation by the U.S. FDA for first-line treatment of advanced biliary tract cancer
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Orphan Drug Designation in Japan
Later from Nanjing Leads Biolabs
- Voluntary announcement phase ii study of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) as first-line treatment for gastric cancer progresses to expansion stage
- Voluntary announcement oral presentation of updated clinical data of LBL-034 for relapsed/refractory multiple myeloma at 2026 ESMO
- Voluntary announcement presentation of updated clinical and translational data of LBL-024 for extrapulmonary neuroendocrine carcinoma, biliary tract cancer and colorectal cancer at 2026 esmo
- Voluntary announcement part B of LBL-047 phase i study completes first dosing of a patient with systemic lupus erythematosus; novel BDCA2/TACI dual-targeting design enters clinical evaluation in patients
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Nanjing Leads Biolabs into a list and get an email when it puts out news.
Follow Nanjing Leads Biolabs